Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 3 | 2 | 5 |
| 2009 | 1 | 0 | 1 |
| 2010 | 4 | 3 | 7 |
| 2011 | 3 | 2 | 5 |
| 2012 | 1 | 4 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 4 | 2 | 6 |
| 2015 | 2 | 5 | 7 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 1 | 3 |
| 2019 | 4 | 1 | 5 |
| 2020 | 1 | 4 | 5 |
| 2021 | 6 | 0 | 6 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024 Jan; 103(1):105-116.
-
Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice. J Med Chem. 2023 12 14; 66(23):16075-16090.
-
Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11. ACS Chem Biol. 2023 04 21; 18(4):803-809.
-
Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma. Cells. 2022 Nov 27; 11(23).
-
Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6. ACS Chem Biol. 2021 12 17; 16(12):2746-2751.
-
Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer. Eur J Med Chem. 2021 Dec 05; 225:113799.
-
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi. Melanoma Res. 2021 08 01; 31(4):319-327.
-
Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Eur J Med Chem. 2021 Nov 15; 224:113672.
-
Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors. ACS Chem Biol. 2021 07 16; 16(7):1266-1275.
-
Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition. Elife. 2021 04 15; 10.